<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8">
    <title></title>
    <link rel="stylesheet" href="../../css/uswds.min.css">
    <link rel="stylesheet" href="../../css/style.css">
  </head>
  <body>

    <header>
        <h2 class="title">
            <a href="../../index.html">Code of Federal Regulations (alpha)</a>
        </h2>
    </header>

    <div class="usa-grid">
      <div class="usa-width-one-whole">
          <h3>
                                <a href="../../index.html">CFR</a><span>&nbsp/&nbsp</span>
                                <a href="../titles/title21.html">
                                    Title 21
                                </a><span>&nbsp/&nbsp</span>
                                <a href="../parts/21CFR201.html">Part 201
                                </a><span>&nbsp/&nbsp<span>
                                Sec. 201.319  Water-soluble gums, hydrophilic gums, and hydrophilic  polycarbophil,carboxymethylcellulose sodium, carrageenan, chondrus,
                            </h3>
                            <p class="depth0">glucomannan ((B-1,4 linked) polymannose acetate), guar gum,</p><p class="depth0">karaya gum, kelp, methylcellulose, plantago seed (psyllium),</p><p class="depth0">polycarbophil tragacanth, and xanthan gum) as active</p><p class="depth0">ingredients; required warnings and directions.</p><p class="depth1"><em>(a)(12)(i)(B)</em> of this chapter) and may not  be marketed without an approved new drug application because the  warnings and directions in paragraph (b) of this section have been found  inadequate for these products.</p><p class="depth1"><em>(b)</em> Any drug products for human use containing a water-soluble gum,  hydrophilic gum, or hydrophilic mucilloid as an active ingredient in an  oral dosage form when marketed in a dry or incompletely hydrated form as  described in paragraph (a) of this section are misbranded within the  meaning of section 502 of the Federal Food, Drug, and Cosmetic Act  unless their labeling bears the following warnings (under the subheading  ``Choking'') and directions:</p><p class="depth2">`` `Choking' [highlighted in bold type]: Taking this product without  adequate fluid may cause it to swell and block your throat or esophagus  and may cause choking. Do not take this product if you have difficulty  in swallowing. If you experience chest pain, vomiting, or difficulty in  swallowing or breathing after taking this product, seek immediate  medical attention;'' and</p><p class="depth2">`` `Directions' [highlighted in bold type]:'' (Select one of the  following, as appropriate: ``Take'' or ``Mix'') ``this product (child or  adult dose) with at least 8 ounces (a full glass) of water or other  fluid. Taking this product without enough liquid may cause choking. See  choking warning.''</p><p class="depth1"><em>(c)</em> After February 28, 1994, any such OTC drug product initially  introduced or initially delivered for introduction into interstate  commerce, or any such drug product that is repackaged or relabeled after  this date regardless of the date the product was manufactured, initially  introduced, or initially delivered for introduction into interstate  commerce, that is not in compliance with this section is subject to  regulatory action.  [58 FR 45201, Aug. 26, 1993, as amended at 64 FR 13292, Mar. 17, 1999;  72 FR 14674, Mar. 29, 2007]</p>
      </div>
    </div>

    <footer class="usa-footer usa-footer-slim" role="contentinfo">
    <div class="usa-grid usa-footer-return-to-top">
      <a href="#">Return to top</a>
    </div>
    <div class="usa-footer-primary-section">
      <div class="usa-grid-full">
        <h5>Built with ‚ù§ by <a href="https://18f.gsa.gov/">18F</a>.
          Code available <a href="https://github.com/18F/allregs">on Github.
        </a></h5>
        <h5>All regulations are from the 2015 Annual Edition.
          This is a technical demonstration not intended for serious use.</h5>
      </div>
    </div>
  </footer>
  </body>
</html>
